Neurogen's aplindore positive in Phase II in Parkinson's and RLS
This article was originally published in Scrip
Executive Summary
Neurogen has reported positive top-line results from its Phase IIa trials of its dopamine partial agonist, aplindore, in the treatment of Parkinson's disease and restless legs syndrome (RLS).